Since the comprehensive recommendations for the management of acute promyelocytic
leukemia (APL) reported in 2009, several studies have provided important insights …

This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim …

Acute myeloid leukaemia (AML) incidence is age dependent, rising markedly in patients
aged! 60 years. Ageing of the European population may therefore contribute to the reported …

The role of allogeneic hematopoietic stem cell transplantation (HCT) in the treatment of
acute myelogenous leukemia (AML) in children is reviewed and critically evaluated in this …

With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) acute
promyelocytic leukemia (APL) has become from a detrimental to one of the most curable …

The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed
adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence …

Simple Summary Acute promyelocytic leukemia (APL) currently benefits from first-line
treatment based on all-trans retinoic acid and arsenic trioxide, ensuring long-term complete …

Acute promyelocytic leukemia (APL) is a special disease entity of acute myeloid leukemia
(AML). The clinical use of all-trans retinoic acid (ATRA) has transformed APL into the most …

We retrospectively compared outcomes of a large series of adult patients with APL in CR2
receiving alloHSCT (n= 228) or autoHSCT (n= 341) reported to the European Society for …

The advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has significantly
improved the outcomes of acute promyelocytic leukemia (APL); nevertheless, a small …